Please select the option that best describes you:
Do you recommend bevacizumab in platinum sensitive recurrences of epithelial ovarian cancer?
Or do you wait for platinum resistance?
Answer from: at Academic Institution
Bevacizumab was approved for use in combination with chemotherapy followed by continued bevacizumab maintenance in patients with platinum-sensitive recurrent ovarian cancer in December 2016. This approval was based on the findings of 2 studies, GOG-213 and the OCEANS trial. Both trials demonstrated ...
Sign in or Register to read more